| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Spero Therapeutics (NASDAQ:SPRO) reported its Q1 earnings results on Monday, May 16, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Spero Therapeutics missed estimated earnings by 16.09%, reporting an EPS of $-1.01 versus an estimate of $-0.87.
Revenue was down $5.23 million from the same period last year.
Last quarter the company missed on EPS by $0.15 which was followed by a 18.28% drop in the share price the next day.
Here's a look at Spero Therapeutics's past performance:
| Quarter | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.75 | -0.66 | -0.77 | -0.64 |
| EPS Actual | -0.90 | -0.70 | -0.63 | -0.66 |
| Revenue Estimate | 4.95M | 4.47M | 4.03M | 3.16M |
| Revenue Actual | 2.74M | 3.06M | 5.15M | 7.30M |
To track all earnings releases for Spero Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: SPRO
